Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Bodyweight gain with atypical antipsychotics. A comparative review.

Wetterling T.

Drug Saf. 2001 Jan;24(1):59-73. Review.

PMID:
11219487
2.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
3.

[Weight gain from atypical neuroleptics--an underreported adverse effect?].

Wetterling T.

Fortschr Neurol Psychiatr. 2000 Dec;68(12):546-56. Review. German.

PMID:
11200858
4.

[Atypical antipsychotic drugs].

Kahn RS.

Ned Tijdschr Geneeskd. 2000 Aug 19;144(34):1627-30. Review. Dutch.

PMID:
10972052
5.

Risperidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2. Review.

6.

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.

Kapur S, Remington G.

Annu Rev Med. 2001;52:503-17. Review.

PMID:
11160792
7.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

8.

Clozapine versus other atypical antipsychotics for schizophrenia.

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006633. doi: 10.1002/14651858.CD006633.pub2. Review.

9.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
10.

Review of atypical antipsychotics and weight gain.

Sussman N.

J Clin Psychiatry. 2001;62 Suppl 23:5-12. Review.

11.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
12.

Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.

Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.

Am J Psychiatry. 2004 Sep;161(9):1620-5.

PMID:
15337652
13.
14.

Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.

Potvin S, Stip E, Roy JY.

Int Clin Psychopharmacol. 2003 May;18(3):121-32. Review.

PMID:
12702890
15.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
16.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
17.

Use of atypical antipsychotics in mood disorders.

Weizman R, Weizman A.

Curr Opin Investig Drugs. 2001 Jul;2(7):940-5. Review.

PMID:
11757795
18.

Ziprasidone versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006627. doi: 10.1002/14651858.CD006627.pub2. Review.

19.
20.

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

Glazer WM.

J Clin Psychiatry. 2000;61 Suppl 3:16-21. Review.

Supplemental Content

Support Center